Search

TYK2 Inhibitor Compound, BeOne Medicines, US12606556B2

The USPTO granted Patent US12606556B2 to BeOne Medicines I GmbH on April 21, 2026, covering a TYK2 inhibitor compound (Formula I) and its pharmaceutical uses for treating inflammatory or autoimmune diseases. The patent contains 17 claims and classifies under CPC C07D 471/04. Inventors are Qiuwen Wang, Yunhang Guo, and Zhiwei Wang. The patent creates intellectual property rights but does not impose compliance obligations on third parties.

Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment

USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.

Patent Application for Benzofuran Derivatives as SIK Inhibitors

The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.